Singapore markets open in 7 hours 16 minutes

Graphite Bio, Inc. (GRPH)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.4100-0.0200 (-0.58%)
As of 12:44PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close3.4300
Open3.4200
Bid3.4000 x 1100
Ask3.4200 x 1100
Day's range3.4000 - 3.5700
52-week range2.0700 - 13.3900
Volume47,626
Avg. volume186,668
Market cap198.299M
Beta (5Y monthly)N/A
PE ratio (TTM)0.66
EPS (TTM)5.1800
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est11.71
  • Business Wire

    Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference

    SOUTH SAN FRANCISCO, Calif., November 21, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that members of the management team will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Thursday, Dec. 1, 2022, at 11:45 a.m. ET.

  • Business Wire

    Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results

    SOUTH SAN FRANCISCO, Calif., November 09, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today reported recent business progress and third quarter 2022 financial results.

  • Business Wire

    Graphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and Exposition

    SOUTH SAN FRANCISCO, Calif., November 03, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that two abstracts have been accepted as part of the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held December 10-13 in New Orleans and broadcast virtually from the E